



## Metachronous Signet Ring Cell Bladder Metastasis as First Sign of Cancer Recurrence


Renán Javier Otta-Oshiro, Fernando Lista-Mateos, Sara Encinas-García, Sonia Morales-García, and Carlos Núñez-Mora

We describe the case of a 74-year-old woman with previous history of gastric signet cell carcinoma who develops bladder metastasis as first sign of recurrence 6 years later. Bladder metastasis due to signet cell carcinoma is extremely rare with only 19 cases reported. Treatment includes radical cystectomy or chemotherapy. *UROLOGY* 134: e1–e2, 2019. © 2019 Elsevier Inc.

### CASE PRESENTATION

A 74-year-old woman with previous history of gastric signet cell carcinoma (SRC) diagnosed in May 2012. Neoadjuvant chemotherapy, total gastrectomy, and adjuvant chemotherapy were performed based on the results of MAGIC trial.<sup>1</sup> Pathology rendered pT3N0 Her2 negative. There was no evidence of recurrence during follow-up.

In June 2018 the patient was referred to the urology department due to a bladder wall thickening observed in a CT scan with no other abnormality (Fig. 1). Cystoscopy



**Figure 1.** Abdominal CT showing bladder wall thickening.

did not show endoluminal lesions. Urine Cytology was negative. Bladder MRI showed suspicious lesion in the right bladder wall. Transurethral resection of the bladder was performed.

Pathologic analysis rendered metastasis of SRC (Fig. 2A). Immunohistochemistry showed GATA-3 negative (Fig. 2B) and CKAE1/AE3 (Fig. 2C) positive reaction. Her2 and PDL-1 were negative. Peritoneal cytology was negative.

Systemic chemotherapy with FOLFOX-6 and radiotherapy were offered.

Five months later peritoneal recurrence was detected and systemic therapy with FOLFOX 6 has been restarted.

Bladder metastasis of SRC is extremely rare and is associated with a dim prognosis.<sup>2</sup> To our knowledge there are only 19 cases reported.<sup>3</sup> Treatment includes cystectomy or systemic therapy.<sup>4</sup>

### References

- Cunningham D, Allum WH, et al. Preoperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med.* 2006;355:11.
- Vigilar E, Marino G, Matano E, Imbimbo C, Rossella de C, Insabato L. Signet ring cell carcinoma of stomach metastatic to the bladder a case report with cytological and histological correlation and literature review. *Int J Surg Pathol.* 2013;21:72–75. <https://doi.org/10.1177/1066896912445922>.
- Okutur K, Eren OO, Demir G. Metastasis of gastric signet ring cell carcinoma to the urinary bladder a case report and review of the liter-

**Conflict of Interest:** There are no conflict of interest.


From the Urology Department, MD Anderson Cancer Center, Madrid, Spain; the Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain; and the Pathology Department, MD Anderson Cancer Center, Madrid, Spain

Address correspondence to: Renán Javier Otta-Oshiro, M.D., Anderson Cancer Center Madrid departamento de urología, Calle Arturo Soria 270, 28033 Madrid, Spain.


E-mail: [rotta@mdanderson.es](mailto:rotta@mdanderson.es)

Submitted: June 16, 2019, accepted (with revisions): September 23, 2019


A



B



C



**Figure 2.** (A) Urothelium with reactive dysplasia. Beneath an expansive infiltrative proliferation of signet ring cell metastatic neoplasia. (B) GATA-3 negative. (C) CKAE1/AE3 positive.

ature. *Case Rep Oncol Med.* 2015;2015: 127516. <https://doi.org/10.1155/2015/127516>.

4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet.* 2010;376:687. [https://doi.org/10.1016/S0140-6736\(10\)61121-X](https://doi.org/10.1016/S0140-6736(10)61121-X). Epub 2010 Aug 19.